Ottawa opens up its drug stockpile - media (Sandoz-sole supplier......)

Ottawa opens up its drug stockpile

"Sandoz is the sole supplier to Canadian hospitals of 90 per cent of all injectable drugs, including more than 100 pain-killers and sedatives."

Ottawa cancer rates highest in Ontario - Health - but best breast cancer survival ratesCBC News

Ottawa press release: (drug GAP-107B8 / ascites) PharmaGap Sees Positive Results from In Vivo Ovarian Cancer Models at the Ottawa Hospital Research Institute

Note: in research  

OTTAWA, ONTARIO--(Marketwire - April 18, 2011) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") today announced initial results from preclinical testing at the Ottawa Hospital Research Institute ("OHRI"). Initial results from this study are positive and provide evidence that a peptide formulation of PharmaGap's lead cancer drug GAP-107B8 administered via the intraperitoneal route can reduce tumour burden (19%) and significantly suppress ascites formation (73%) relative to controls. The test was undertaken at OHRI in collaboration with Dr. Barbara Vanderhyden. Dr. Vanderhyden, upon initial review of the data commented "The reduction in ascites volume is very interesting in its own right, because this is a notable cause of morbidity in women with ovarian cancer. There is currently no drug therapy that is effective against ovarian cancer-associated ascites accumulation. Paracentesis, the removal of abdominal ascites, is commonly used to alleviate symptoms and prolong survival of women with ovarian cancer.......

.........In this study two formulations of GAP-107B8 peptides were tested in an established intraperitoneal xenograft model in immune-deficient mice and evaluated for tumour burden and accumulation of malignant ascites (excess fluid containing cancer cells in the abdominal cavity). The cell line selected for testing (OCC-1 human ovarian cancer) is of a phenotype characterized by the production of peritoneal ascites with growth of multiple small solid tumours......

Cochrane Canada Symposium (includes consumers/patients)

Subject: Cochrane Canada Symposium

Workshop: Cochrane Canada 8th Annual Symposium - Evidence in Uncertain Times: Meeting the Challenge
Date: 19-20 May 2010, Presymposium: 17-18 May 2010
Location: Ottawa, Ontario, Canada
Details: We invite researchers, health policy makers and managers, health professionals, and patients to join the Canadian Cochrane Centre as we discuss Evidence in Uncertain Times at our 8th annual symposium. Abstract submission for workshop, oral and poster presentations is open until 12 February 2010. Early Bird registration ends on 19 March 2010
Email: ccnc.symposium@uottawa.ca
Website: www.ccncsymposium.com 

Women's decision-making needs related to treatment for recurrent ovarian cancer: a pilot study

"abstract:
The purpose of this pilot study was to describe the decision-making needs of women with ovarian cancer related to treatment of recurrent disease. ..... CONCLUSIONS: The findings provide some beginning direction for an inter-professional decision support approach, as well as implications for future research.